By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Use. You can change your cookie settings through your browser.
I agree
Search Trends
CHOOSE YOUR LANGUAGE
- Albanian Shqip
- Arabic ???????
- Belarusian Беларуская
- Bengali ?????
- Bulgarian Български
- Cambodian ?????
- Croatian Hrvatski
- Czech ?esky
- English English
- Esperanto Esperanto
- Filipino Filipino
- French Fran?ais
- German Deutsch
- Greek Ελληνικ?
- Hausa Hausa
- Hebrew ?????
- Hungarian Magyar
- Hindi ??????
- Indonesian Bahasa Indonesia
- Italian Italiano
- Japanese 日本語
- Korean ???
- Lao ???
- Malay Bahasa Melayu
- Mongolian Монгол
- Myanmar ??????????
- Nepali ??????
- Persian ?????
- Polish Polski
- Portuguese Português
- Pashto ????
- Romanian Roman?
- Russian Русский
- Serbian Српски
- Sinhalese ?????
- Spanish Espa?ol
- Swahili Kiswahili
- Tamil ?????
- Thai ???
- Turkish Türk?e
- Ukrainian Укра?нська
- Urdu ????
- Vietnamese Ti?ng Vi?t
Copyright ? 2024 CGTN.
京ICP备20000184号
CHOOSE YOUR LANGUAGE
- Albanian Shqip
- Arabic ???????
- Belarusian Беларуская
- Bengali ?????
- Bulgarian Български
- Cambodian ?????
- Croatian Hrvatski
- Czech ?esky
- English English
- Esperanto Esperanto
- Filipino Filipino
- French Fran?ais
- German Deutsch
- Greek Ελληνικ?
- Hausa Hausa
- Hebrew ?????
- Hungarian Magyar
- Hindi ??????
- Indonesian Bahasa Indonesia
- Italian Italiano
- Japanese 日本語
- Korean ???
- Lao ???
- Malay Bahasa Melayu
- Mongolian Монгол
- Myanmar ??????????
- Nepali ??????
- Persian ?????
- Polish Polski
- Portuguese Português
- Pashto ????
- Romanian Roman?
- Russian Русский
- Serbian Српски
- Sinhalese ?????
- Spanish Espa?ol
- Swahili Kiswahili
- Tamil ?????
- Thai ???
- Turkish Türk?e
- Ukrainian Укра?нська
- Urdu ????
- Vietnamese Ti?ng Vi?t
Copyright ? 2024 CGTN.
京ICP备20000184号
互联网新闻信息许可证10120180008
Disinformation report hotline: 010-85061466
China's biotechnology industry is emerging as a global powerhouse, according to Chen Ziyi, head of Asia healthcare research at Goldman Sachs. About one-third of drug candidates in active clinical trials worldwide are now Chinese-developed, with 50 percent of new assets entering human studies in the first half of 2025 originating from China. This wave of innovation is driving a boom in cross-border licensing, with 20-30 deals per quarter placing Chinese biotech assets in global markets.